# A Phase IIa Multi-Center Study of 18F-FDG PET, Safety, and Tolerability of AZD0530 in Mild Alzheimer's Disease

> **NCT02167256** · PHASE2 · COMPLETED · sponsor: **Yale University** · enrollment: 159 (actual)

## Conditions studied

- Alzheimer's Disease

## Interventions

- **DRUG:** AZD0530 100mg daily
- **DRUG:** AZD0530 125mg daily
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02167256
- **Lead sponsor:** Yale University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-12
- **Primary completion:** 2018-02-27
- **Final completion:** 2018-02-27
- **Target enrollment:** 159 (ACTUAL)
- **Last updated:** 2019-08-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02167256

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02167256, "A Phase IIa Multi-Center Study of 18F-FDG PET, Safety, and Tolerability of AZD0530 in Mild Alzheimer's Disease". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02167256. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*